Elsevier

Clinica Chimica Acta

Volume 209, Issue 3, 31 August 1992, Pages 153-167
Clinica Chimica Acta

Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: Evidence for reduced pineal activity and relevance of urinary determinations

https://doi.org/10.1016/0009-8981(92)90164-LGet rights and content

Abstract

The circadian rhythms of melatonin and 6-sulfatoxymelatonin (aMT6s) were analyzed in serum and urine of young men (YM, n = 8), of elderly patients with benign prostatic hyperplasia (BPH, n = 7) and of patients of similar age with primary prostate cancer (PC, n = 9). The data expressed as concentration and in urine also as hourly excreted quantity were analyzed chronobiologically by the single cosinor method and, subsequently submitted to linear regression analyses. Circadian rhythms were detected in all cases except for the excreted quantity of melatonin. The circadian patterns of melatonin and aMT6s in serum were very similar in the different groups and regression analyses showed close correlations between both variables. MESOR and amplitude were significantly depressed in PC (40–60%) as compared to BPH and YM indicating that the depression of serum melatonin in PC is due to a reduced pineal activity and is not caused by an enhanced metabolic degradation in the liver. Acrophases of serum melatonin occurred between 01:34 and 03:26 h and of serum aMT6s between 03:58 and 04:35 h. Circadian rhythms similar to those of serum melatonin and aMT6s were found in urine, particularly for aMT6s excretion as well as melatonin concentration; the determination of both parameters in overnight urine samples closely correlated with the nocturnal peak of circulating melatonin. These results imply that it is feasible to estimate changes in pineal function of prostate cancer patients by means of non-invasive determinations using urinary melatonin and aMT6s.

References (42)

  • C Bartsch et al.

    Pineal melatonin synthesis and secretion during induction and growth of mammary cancer in female rats

  • C Bartsch et al.

    Urinary melatonin levels in human breast cancer patients

    J Neural Transm

    (1981)
  • L Tamarkin et al.

    Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer

    Science

    (1982)
  • C Bartsch et al.

    Stage-dependent depression of melatonin in patients with primary breast cancer: Correlation with prolactin, thyroid stimulating hormone and steroid receptors

    Cancer

    (1989)
  • C Bartsch et al.

    Circadian rhythms of serum melatonin, prolactin and growth hormone in patients with benign and malignant tumors of the prostate and in non-tumor controls

    Neuroendocrinol Lett

    (1983)
  • C Bartsch et al.

    Evidence for modulation of melatonin secretion in men with benign and malignant tumors of the prostate: relationship with the pituitary hormones

    J Pineal Res

    (1984)
  • IM Kvetnoy et al.

    Diurnal melatonin excretion in gastric and rectal cancer patients

    Vop Onkol SSSR

    (1987)
  • R Khoory et al.

    Plasma melatonin levels in patients suffering from colorectal carcinoma

    J Pineal Res

    (1988)
  • U Weinberg et al.

    Ontogeny of melatonin metabolism in the rat

  • C Bartsch et al.

    Effect of the mammary carcinogen 7,12-dimethylbenz[a]anthracene on pineal melatonin biosynthesis, secretion and peripheral metabolism

    Neuroendocrinology

    (1990)
  • C Bartsch et al.

    Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism

    Cancer

    (1991)
  • Cited by (105)

    • Physiological melatonin levels in healthy older people: A systematic review

      2016, Journal of Psychosomatic Research
      Citation Excerpt :

      The maximum levels varied greatly. ( See Fig. 2) Mazzoccoli [10,39] showed peak levels of approximately 90 pg ml− 1, 3 studies [26,27,9] showed maximum levels around 60 pg ml− 1 and the lowest maximum level was found by Iguichi, 11.2 pg ml− 1. [41] In Fig. 3 the (weighted) mean melatonin concentration in twenty-four hours is presented.

    • Geographically-weighted regression analysis of percentage oflate-stage prostate cancer diagnosis in Florida

      2015, Applied Geography
      Citation Excerpt :

      An important factor associated with high percentage of late-stage PCa is the presence and severity of comorbidity. Comorbidity is the co-occurrence of one or more diseases or disorders in an individual (Bartsch et al., 1992; Siu, Lau, Tam, & Shiu, 2002). Comorbidity reflects the aggregate effect of all clinical conditions a patient might have, excluding the disease of primary interest (Arcangeli, Smith, Ratliff, & Catalona, 1997).

    View all citing articles on Scopus

    Present address: Section of Clinical Pharmacology, Department of Gynecology, University of Tübingen, W-7400 Tübingen, Germany.

    View full text